Rock Creek Group LP Buys 101 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Rock Creek Group LP lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.4% in the second quarter, HoldingsChannel.com reports. The firm owned 855 shares of the medical research company’s stock after purchasing an additional 101 shares during the quarter. Rock Creek Group LP’s holdings in Thermo Fisher Scientific were worth $431,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $26,000. MV Capital Management Inc. grew its stake in Thermo Fisher Scientific by 577.8% during the second quarter. MV Capital Management Inc. now owns 61 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 52 shares in the last quarter. Bedel Financial Consulting Inc. lifted its stake in Thermo Fisher Scientific by 65.0% in the 2nd quarter. Bedel Financial Consulting Inc. now owns 66 shares of the medical research company’s stock worth $33,000 after purchasing an additional 26 shares in the last quarter. Lake Point Wealth Management purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $34,000. Finally, FFT Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth about $35,000. Institutional investors own 85.50% of the company’s stock.

In related news, Director Jim P. Manzi sold 572 shares of the firm’s stock in a transaction on Friday, July 30th. The stock was sold at an average price of $536.54, for a total value of $306,900.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, August 4th. The stock was sold at an average price of $539.05, for a total value of $5,390,500.00. The disclosure for this sale can be found here. 0.44% of the stock is currently owned by company insiders.

A number of equities research analysts recently issued reports on the stock. Benchmark initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, July 16th. They set a “buy” rating and a $580.00 price target on the stock. KeyCorp boosted their target price on Thermo Fisher Scientific from $520.00 to $555.00 and gave the company an “overweight” rating in a research report on Monday, July 12th. Cowen increased their target price on shares of Thermo Fisher Scientific from $525.00 to $560.00 and gave the company an “outperform” rating in a research note on Thursday, July 29th. The Goldman Sachs Group reduced their price objective on shares of Thermo Fisher Scientific from $590.00 to $530.00 and set a “buy” rating on the stock in a research report on Tuesday, June 15th. They noted that the move was a valuation call. Finally, Zacks Investment Research lowered Thermo Fisher Scientific from a “hold” rating to a “strong sell” rating and set a $491.00 price target for the company. in a research note on Monday, July 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $547.95.

Shares of NYSE TMO opened at $562.40 on Wednesday. The business has a fifty day moving average price of $542.01 and a 200 day moving average price of $494.08. Thermo Fisher Scientific Inc. has a 1-year low of $412.80 and a 1-year high of $575.63. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.78 and a quick ratio of 2.11. The stock has a market capitalization of $221.26 billion, a P/E ratio of 26.07, a price-to-earnings-growth ratio of 1.33 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 28th. The medical research company reported $5.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.51 by $0.09. Thermo Fisher Scientific had a net margin of 22.47% and a return on equity of 29.43%. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.07 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 15th. Investors of record on Wednesday, September 15th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 5.32%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Read More: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.